Trial Profile

A Multicenter, Single-Arm, Open-Label Phase I Clinical Study of Pelareorep With Paclitaxel in Advanced or Metastatic Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Pelareorep (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions
Sponsors Adlai Nortye

Most Recent Events

21 Nov 2023 Status changed from active, no longer recruiting to completed.
10 Dec 2022 Results (at data cutoff date off: 3 June 2022; n=10) presented at the 45th Annual San Antonio Breast Cancer Symposium.
21 Nov 2022 According to an Oncolytics Biotech media release, Updated and additional data from the trial will be presented in the poster corresponding to the abstract in accordance with the SABCS embargo policies.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com